ICER, unconvinced by Biogen data, suggests low price for Alzheimer's drug

https://www.biopharmadive.com/news/icer-biogen-aducanumab-price-alzheimers/599612/

 

Not Good! Just call it for what it is. Docs won't justify adding yet another drug cost to a patient when they are already taking other meds. Insurance plans wouldn't justify it either unless its free and that certainly won't account for the added headcount of a salesforce or launch.

 

With today’s out of control inflation, this drug will be priced less than aspirin if it gets approved - too cheap to even have a salesforce